KR102877857B1 - 치환된 크산틴 유도체 - Google Patents
치환된 크산틴 유도체Info
- Publication number
- KR102877857B1 KR102877857B1 KR1020217021875A KR20217021875A KR102877857B1 KR 102877857 B1 KR102877857 B1 KR 102877857B1 KR 1020217021875 A KR1020217021875 A KR 1020217021875A KR 20217021875 A KR20217021875 A KR 20217021875A KR 102877857 B1 KR102877857 B1 KR 102877857B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- mixture
- added
- esi
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212060.0 | 2018-12-12 | ||
| EP18212060 | 2018-12-12 | ||
| PCT/EP2019/084375 WO2020120450A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210102955A KR20210102955A (ko) | 2021-08-20 |
| KR102877857B1 true KR102877857B1 (ko) | 2025-10-29 |
Family
ID=64665184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217021875A Active KR102877857B1 (ko) | 2018-12-12 | 2019-12-10 | 치환된 크산틴 유도체 |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12064917B2 (en) | 2012-11-21 | 2024-08-20 | Stratasys, Inc. | Method for printing three-dimensional parts with cyrstallization kinetics control |
| IL283768B2 (en) * | 2018-12-12 | 2024-05-01 | Boehringer Ingelheim Int | Xanthine histories are transmuted |
| KR20250141831A (ko) * | 2023-02-08 | 2025-09-29 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 잔틴계 화합물 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX370372B (es) | 2013-03-15 | 2019-12-11 | Hydra Biosciences Inc | Xantinas sustituidas y metodos de uso de las mismas. |
| EP3180340B1 (en) | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| JP7114702B2 (ja) * | 2017-07-11 | 2022-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換キサンチン誘導体 |
| IL283768B2 (en) * | 2018-12-12 | 2024-05-01 | Boehringer Ingelheim Int | Xanthine histories are transmuted |
-
2019
- 2019-12-10 IL IL283768A patent/IL283768B2/en unknown
- 2019-12-10 AU AU2019396499A patent/AU2019396499B2/en not_active Ceased
- 2019-12-10 JP JP2021533340A patent/JP7502299B2/ja active Active
- 2019-12-10 WO PCT/EP2019/084375 patent/WO2020120450A1/en not_active Ceased
- 2019-12-10 PL PL19820718.5T patent/PL3894410T3/pl unknown
- 2019-12-10 HU HUE19820718A patent/HUE064908T2/hu unknown
- 2019-12-10 ES ES19820718T patent/ES2964630T3/es active Active
- 2019-12-10 PH PH1/2021/551345A patent/PH12021551345A1/en unknown
- 2019-12-10 KR KR1020217021875A patent/KR102877857B1/ko active Active
- 2019-12-10 EA EA202191588A patent/EA202191588A1/ru unknown
- 2019-12-10 BR BR112021008316-2A patent/BR112021008316A2/pt unknown
- 2019-12-10 EP EP19820718.5A patent/EP3894410B1/en active Active
- 2019-12-10 CN CN201980081737.1A patent/CN113166151B/zh active Active
- 2019-12-10 MX MX2021007019A patent/MX2021007019A/es unknown
- 2019-12-10 DK DK19820718.5T patent/DK3894410T3/da active
- 2019-12-11 US US16/710,887 patent/US11198696B2/en active Active
- 2019-12-12 TW TW108145593A patent/TWI825243B/zh active
-
2021
- 2021-06-09 CL CL2021001509A patent/CL2021001509A1/es unknown
- 2021-11-10 US US17/523,316 patent/US20220177479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL3894410T3 (pl) | 2024-03-18 |
| HUE064908T2 (hu) | 2024-04-28 |
| ES2964630T3 (es) | 2024-04-08 |
| BR112021008316A2 (pt) | 2021-08-03 |
| KR20210102955A (ko) | 2021-08-20 |
| US11198696B2 (en) | 2021-12-14 |
| CN113166151A (zh) | 2021-07-23 |
| DK3894410T3 (da) | 2023-11-27 |
| IL283768A (en) | 2021-07-29 |
| CN113166151B (zh) | 2023-12-01 |
| TWI825243B (zh) | 2023-12-11 |
| JP7502299B2 (ja) | 2024-06-18 |
| CA3119229A1 (en) | 2020-06-18 |
| EP3894410B1 (en) | 2023-10-11 |
| EP3894410A1 (en) | 2021-10-20 |
| TW202039495A (zh) | 2020-11-01 |
| US20200190093A1 (en) | 2020-06-18 |
| MX2021007019A (es) | 2021-09-10 |
| IL283768B1 (en) | 2024-01-01 |
| US20220177479A1 (en) | 2022-06-09 |
| WO2020120450A1 (en) | 2020-06-18 |
| CL2021001509A1 (es) | 2021-12-17 |
| PH12021551345A1 (en) | 2022-05-11 |
| AU2019396499A1 (en) | 2021-05-27 |
| AU2019396499B2 (en) | 2024-10-10 |
| IL283768B2 (en) | 2024-05-01 |
| JP2022512373A (ja) | 2022-02-03 |
| EA202191588A1 (ru) | 2021-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113227068B (zh) | Glp-1r激动剂及其用途 | |
| CN110461830B (zh) | Jak1选择性抑制剂 | |
| CA2828478A1 (en) | Serine/threonine kinase inhibitors | |
| CN109526220B (zh) | 用于治疗疼痛和疼痛相关的状况的四氢嘧啶并二氮杂䓬和四氢吡啶并二氮杂䓬化合物 | |
| CN106470985A (zh) | 作为可溶性鸟苷酸环化酶激活剂的茚满和二氢吲哚衍生物及其用途 | |
| ES2903268T3 (es) | Derivados de xantina sustituida | |
| TW201925204A (zh) | 稠合三環化合物 | |
| KR20210102955A (ko) | 치환된 크산틴 유도체 | |
| JP7408662B2 (ja) | 置換キサンタン誘導体 | |
| TW201504227A (zh) | 環狀胺基甲基嘧啶衍生物 | |
| WO2021115495A1 (zh) | 一种小分子含硫杂环化合物 | |
| WO2024207945A1 (zh) | 作为aak1抑制剂的氮杂环类化合物 | |
| CN105793249B (zh) | 用于治疗或预防精神病学和神经病学疾患的哌啶衍生物 | |
| CA3119229C (en) | Substituted xanthine derivatives | |
| HK40110795A (en) | Fused ring compounds | |
| HK40109856A (en) | Fused ring compounds | |
| HK40110213A (en) | Fused ring compounds | |
| HK40110226A (en) | Fused ring compounds | |
| EA043969B1 (ru) | Замещенные ксантиновые производные | |
| KR20260043134A (ko) | Sstr4의 작용제로서 (2s,5r)-5-(하이드록시메틸)모르폴린-2-카복스아미드 | |
| HK40041215B (en) | Fused ring compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |